Publications by authors named "P Reigan"

AMP-activated protein kinase (AMPK) is a central mediator of cellular metabolism and is activated in direct response to low ATP levels. Activated AMPK inhibits anabolic pathways and promotes catabolic activities that generate ATP through the phosphorylation of multiple target substrates. AMPK is a therapeutic target for activation in several chronic metabolic diseases, and there is increasing interest in targeting AMPK activity in cancer where it can act as a tumor suppressor or conversely it can support cancer cell survival.

View Article and Find Full Text PDF

Targeted kinase inhibitors are well known for their promiscuity and off-target effects. Herein, we define an off-target effect in which several clinical BRAF inhibitors, including the widely used dabrafenib and encorafenib, interact directly with GCN2 to activate the Integrated Stress Response and ATF4. Blocking this off-target effect by co-drugging with a GCN2 inhibitor in A375 melanoma cells causes enhancement rather than suppression of cancer cell outgrowth, suggesting that the off-target activation of GCN2 is detrimental to these cells.

View Article and Find Full Text PDF

Parkinson's disease (PD) is the most common neurodegenerative movement disorder worldwide. Current treatments for PD largely center around dopamine replacement therapies and fail to prevent the progression of pathology, underscoring the need for neuroprotective interventions. Approaches that target neuroinflammation, which occurs prior to dopaminergic neuron (DAn) loss in the substantia nigra (SN), represent a promising therapeutic strategy.

View Article and Find Full Text PDF
Article Synopsis
  • Parkinson's disease (PD) is the most common neurodegenerative movement disorder, and current treatments primarily involve dopamine replacement, which do not prevent disease progression.
  • Researchers investigated the glucocorticoid receptor (GR) modulator PT150 for its neuroprotective effects against neuroinflammation in a mouse model of PD, hypothesizing that it would protect dopamine neurons and reduce toxic protein accumulation.
  • The study found that PT150 treatment decreased dopamine neuron loss and microgliosis in the area of the brain affected by PD, demonstrating its potential as a neuroprotective strategy in this context.
View Article and Find Full Text PDF

Giardia lamblia is a deeply branching protist and a human pathogen. Its unusual biology presents the opportunity to explore conserved and fundamental molecular mechanisms. We determined the structure of the G.

View Article and Find Full Text PDF